Stem Cell Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Stem Cell Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Raynaud Syndrome
Raynaud syndrome in patients with systemic sclerosis may be improved by atorvastatin
August 14th, 2006
Raynaud syndrome in patients with systemic sclerosis (SSc) may be improved by atorvastatin. Researchers in Japan conducted a study "to evaluate whether atorvastatin can increase bone marrow-derived circulating endothelial precursors (CEPs) and improve the vascular symptoms in patients with SSc; scleroderma. The study was designed as an open-label, prospective study involving 14 patients with SSc who received 10 mg/day of atorvastatin for 12 weeks and were followed up for the subsequent 4 weeks." "CEPs were quantified at weeks 0 (pretreatment), 4, 8, 12 (during treatment), and 16 (post-treatment) by cell sorting followed by 3-color flow cytometry....
Source: Stem Cell Week (2006-08-14)
|
